Insert your
Directorate or
Department here



**Issue number: Version 1** 

Subject:Guideline for Treating and Monitoring Hypercalcaemia in patients in noncritical areas of Hospital

**Objective:** The objective of this guideline is to provide a clear quick reference

guide to support clinicians in the treatment and monitoring of patients with hypercalcaemia as well as how to investigate causes (serum

adjusted calcium >2.60mmol/L)

Target Level: Trust-wide

Prepared by: Chemical Pathology/Clinical Nutrition

Dr V Mishra, Consultant Chemical Pathologist

John Bassett, Chemical Pathology / Metabolic Medicine ST3

'CG Approved' logo will be added by CG Dept.

Evidence Base: Rank: A, B, C or D (CSG/CG Dept will categorise

evidence base)

**Associated Documents:** 

REVIEW HISTORY				
Issue No.	Page	Changes made with rationale and impact on practice	Date	

# Introduction:


Hypercalcaemia (defined as serum adjusted calcium >2.60 mmol/L) commonly encountered in clinical practice. Most patients with mild hypercalcaemia (serum adjusted calcium between 2.60mmol/L to 2.90mmol/L) are usually asymptomatic. Moderate to severe hypercalcaemia (serum adjusted calcium >3.00mmol/L) can present with dehydration, thirst, polyuria and confusion.

**Causes**: primary hyperparathyroidism, malignancy, calcium and vitamin D supplementation, sarcoidosis, tertiary hyperparathyroidism, prolonged immobilisation, drugs such as thiazides, lithium.

**Exclude:** spurious causes e.g., contamination from drip containing calcium

**Check:** serum adjusted calcium, U&E, eGFR, Magnesium, PTH and 25OH vitamin D prior to treatment if cause of hypercalcaemia unclear. Consider performing myeloma screen: FBC, ESR, serum Immunoglobulins, urine Bence Jones protein, serum electrophoresis

# DO NOT USE THIS GUIDANCE FOR PATIENTS WITH eGFR <30 or PATIENTS WITH CCF, CONTACT RENAL OR CARDIOLOGY TEAM FOR ADVICE



4) Further

management

If serum adjusted calcium shows poor response by day 5 post-IV Zoledronic acid or Pamidronate:

- a. Do not repeat IV bisphosphonate without Consultant review
- b. Contact Clinical Biochemistry (RLUH) or Endocrinology team (AUH)
- c. If patient has primary hyperparathyroidism, this will not respond to fluids or bisphosphonates, so contact Endocrine team for management plan.

#### **APPENDIX**

- a. IV Zoledronic acid dose is 4mg if serum creatinine <400micromol/L, do not give if serum creatinine is 400mmol/L or above.
- b. Give recommended IV Zoledronic acid dose in 100ml of 0.9% saline over 15-60 minutes

## **Pamidronate**

- a. Dose depends on initial adjusted calcium level (Table 2).
- b. Give recommended IV Pamidronate dose in 500ml 0.9% saline over 4 hours.
- c. If creatinine clearance 30 90, no dose adjustment is required.

Table 2: Pamidronate dose according to initial Calcium concentration

Initial adjusted serum calcium	Recommended dose	total
(mmol/litre)	(mg)	
up to 3.0	15-30	
3.0-3.5	30-60	
3.5-4.0	60-90	
>4.0	90	

## Calcitonin

- a. If repeat serum adjusted calcium >4.0mmol/L and patient symptomatic, consider giving Calcitonin (Discuss with Consultant).
- b. It has rapid hypocalcaemic effect and can be given in this situation
- c. It can be given if eGFR<30
- d. Dose: subcutaneous Calcitonin 100units 3 times a day for 5 days

After Calcitonin or bisphosphonate therapy, continue rehydration with 0.18% NaCl-4% dextrose: 2-3L daily for 48 hours, then review.